Table 1.
Descriptive Parameters of 141 Adult Patients with Acute Myeloid Leukemia
| Frequency (%) | |
|---|---|
| Age (n=141) | |
| ≤40 | 69 (48.9) |
| >40 | 72 (51.1) |
| Median (range) | 41.0 (18-74) |
| Gender (n=141) | |
| Female | 65 (46.1) |
| Male | 76 (53.9) |
| TLC (n=137) | |
| ≤100 X109/L | 97 (70.8) |
| >100x109/L | 40 (29.2) |
| Median (range) | 33 (1.38-452.9) |
| Hemoglobin (n=137) | |
| ≤10 g/dl | 123 (89.8) |
| >10 g/dl | 14 (10.2) |
| Median (range) | 7.3 (3.5-15.7) |
| Platelets (n=137) | |
| ≤100x109/L | 112 (81.8) |
| >100x109/L | 25 (18.2) |
| Median (range) | 45.0 (2.0-312.0) |
| Pb blast % (n=141) | |
| ≤50 | 37 (26.2) |
| >50 | 104 (73.8) |
| Median (range) | 70.0 (5.0-99.0) |
| BM blast% (n=141) | |
| ≤50 | 20 (14.2) |
| >50 | 121 (85.8) |
| Median (range) | 76.0 (20.0-98.0) |
| Cellularity (141) | |
| Hypercellular | 120 (85.1) |
| Normocellular | 13 (9.2) |
| Hypocellular | 8 (5.7) |
| FAB Classification (141) | |
| M0 | 4/141 (2.8) |
| M1 | 31/141 (22.0) |
| M2 | 41/141 (29.1) |
| M4 | 47/141 (33.3) |
| M5 | 15/141 (10.6) |
| M7 | 1/141 (0.7) |
| MPAL | 2 (1.4) |
| FAB Classification (134) | |
| M1&M2 | 72 (53.7) |
| M4&M5 | 62 (46.3) |
| Complete Remission (100) | |
| CR | 51 (51.0) |
| NO CR | 49 (49.0) |
| Lymphadenopathy (134) | |
| No | 78 (58.2) |
| Yes | 56 (41.8) |
| Organomegaly (134) | |
| No | 85 (63.4) |
| Yes | 49 (36.6) |
| Frequency (%) | |
| FLT3-ITD (141) | |
| Wild | 96 (68.1) |
| Mutant | 45 (31.9) |
| ITD ratio (n= 45) | |
| ≤0.525 | 20 (44.4) |
| >0.525 | 25 (55.6) |
| Median (range) | 0.58 (0.05-4.94) |
| FLT3-TKD (140) | |
| Wild | 134 (95.7) |
| Mutant | 6 (4.3) |
| NPM (128) | |
| Wild | 107 |
| Mutant | 21 |
| NPM&FLT3 (128) | |
| Favourable | 17 (13.3) |
| Unfavorable | 13 (10.2) |
| Intermediate | 98 (76.6) |
| DNMTA (139) | |
| Wild | 125 (89.9) |
| Mutant | 14 (10.1) |
| IDH1 (141) | |
| Wild | 136 (96.5) |
| Mutant | 5 (3.5) |
| IDH2 (141) | |
| Wild | 135 (95.7) |
| Mutant | 6 (4.3) |
| IDH1&IDH2 (141) | |
| Wild | 130 (92.2) |
| Mutant | 11 (7.8) |
| TET2 (141) | |
| Wild | 69 (48.9) |
| Mutant | 72 (51.1) |
| TET2 (141) | |
| Hetero | 57 (40.4) |
| Homo | 15 (10.7) |
| Wild | 69 (48.9) |
| CD34 (140) | |
| Positive | 69 (49.3) |
| Negative | 71 (50.7) |
| Dr (140) | |
| Positive | 100 (71.4) |
| Negative | 40 (28.6) |
| CD7 (140) | |
| Positive | 23 (16.4) |
| Negative | 117 (83.6) |
| OS time (months) median (range) | 2.07 (0.10-40.72) |
PB, peripheral blood; TLC, total leukocyte count; BM,bone marrow; CR, complete remission; OS, Overall survival; FLT3-ITD, FMS-like tyrosine kinase3internal tandem duplication; FLT3-TkD, FMS-like tyrosine kinase3 tyrosine kinase domain; IDH, Isocitrate dehydrogenase; TET2, Ten–Eleven Translocation gene2; NPM1, Nucleophosmin; DNMTA, DNA Methyltransferase